Clinical trial
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas…
NCT00499720 · Gilead Sciences, Industry · Approved for marketing
Key facts
| NCT number | NCT00499720 |
|---|---|
| Title | Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection |
| Official title | Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection |
| Intervention type | Drug |
| Interventions | Aztreonam Lysine for Inhalation |
| First posted | Jul 11, 2007 |
| Last update posted | Aug 2, 2011 |
| Countries | Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: